Fampyra is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine).
Studies reveal that the sustained release formulation increases conduction of damaged nerves, which results in improved walking ability.
Fampyra can be used alone or in combination with immunomodulatory drugs.
Fampyra was developed by Acorda Therapeutics and is commercialized in the US under the trade name Ampyra (dalfampridine) Extended Release Tablets, 10mg.